544220 CTLLAB
C

Clinitech Laboratory Share Price

₹65.00 -1.5 (-2.26%)

24 Feb, 2025 12:41

SIP TrendupStart SIP in CTLLAB

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -2.14%
  • Over 3 Month -17.72%
  • Over 6 Month -23.35%
SIP Lightning

Smart Investing Starts Here Start SIP with Clinitech Laboratory for Steady Growth!

Invest Now

Clinitech Laboratory Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Clinitech Laboratory Financials

Loading...

Clinitech Laboratory Technicals

EMA & SMA

Current Price
₹65.00
-1.5 (-2.26%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹73.01
  • 50 Day
  • ₹76.22
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

66.03 Pivot Speed
  • R3 71.37
  • R2 69.43
  • R1 67.97
  • S1 64.57
  • S2 62.63
  • S3 61.17

What's your outlook on Clinitech Laboratory?

You can only vote for once

Clinitech Laboratory Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Half Yearly Results

Clinitech Laboratory F&O

Clinitech Laboratory Shareholding Pattern

No data available.

About Clinitech Laboratory

  • NSE Symbol
  • CTLLAB
  • BSE Symbol
  • 544220
  • ISIN
  • INE0QMR01015

Similar Stocks to Clinitech Laboratory

Clinitech Laboratory FAQs

Clinitech Laboratory share price is ₹65 As on 24 February, 2025 | 12:27

The Market Cap of Clinitech Laboratory is ₹14.8 Cr As on 24 February, 2025 | 12:27

The P/E ratio of Clinitech Laboratory is 40 As on 24 February, 2025 | 12:27

The PB ratio of Clinitech Laboratory is 4.7 As on 24 February, 2025 | 12:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23